Author: Frank Salvato

There is a growing and largely underexamined risk emerging in the technology sector—one that doesn’t arrive with the spectacle of a cyberattack or the visibility of a trade war headline. Instead, it is being embedded quietly, piece by piece, into the hardware powering the next generation of artificial intelligence. As U.S. companies race to compete in AI, some are increasingly turning to chips and components developed in Communist China. That decision may offer short-term cost savings or supply chain flexibility, but it introduces long-term vulnerabilities that deserve serious scrutiny. At the heart of the issue is not simply where a…

Artificial intelligence is poised to dramatically reshape advanced scientific research by enabling PhD students and researchers to complete years of work in a fraction of the time, according to the chief executive of Cusp AI, a rapidly growing materials science company. Instead of spending the first year of a doctoral program combing through thousands of research papers, AI agents can now summarize decades of published literature within seconds, generate promising hypotheses, identify optimal regions of chemical space, and run thousands of simulations simultaneously before laboratory validation begins. The technology is already being applied to real-world challenges, including developing new materials…

A new bipartisan initiative called RAISE US, backed by major tech firms, corporations, and state governments, aims to prepare American workers for widespread job changes driven by artificial intelligence. Led by former officials including Gina Raimondo and Eric Holcomb, the group has secured over $500 million to pilot programs across states like Arkansas, Maryland, Utah, and Connecticut. These efforts focus on retraining, updating outdated policies such as unemployment insurance, and testing incentives for employers to retain and reskill staff rather than replace them, while addressing the fragmented nature of current workforce development systems. Proponents highlight AI’s potential benefits alongside risks…

German Merck has agreed to purchase American company Bio-Techne for approximately $11.3 billion in cash, marking one of its largest acquisitions in over a decade aimed at expanding its capabilities in research tools, reagents, and advanced therapies essential for drug development. The deal offers Bio-Techne shareholders $73 per share, representing a significant premium, and is expected to close by late 2026 or early 2027 subject to approvals, with Merck anticipating cost savings and strengthened positioning in high-growth areas like cell and gene therapy amid robust demand for innovative biotech solutions. Sources Key Takeaways In-Depth In a clear demonstration of vibrant…

A new venture founded by former Anthropic researchers is challenging the stranglehold of elite AI labs by developing tools that let scientists build their own specialized artificial intelligence models, raising $200 million in seed funding at a $1 billion valuation to accelerate self-improving AI research accessible beyond Silicon Valley insiders. Sources Key Takeaways In-Depth In an era where a handful of powerful AI companies hoard the most advanced tools while preaching openness, a group of Anthropic veterans is striking a blow for real innovation. Mirendil, led by co-founders Behnam Neyshabur and Harsh Mehta along with team members from xAI and…

BlackBerry is capitalizing on surging demand for reliable, safety-certified embedded software as companies integrate artificial intelligence into vehicles, industrial machinery, robotics, and other critical systems, raising its fiscal 2027 revenue growth outlook to 8-13% amid strong first-quarter results and expanding opportunities in its general embedded management platform. Sources Key Takeaways In-Depth BlackBerry, long shed of its outdated smartphone image, is quietly emerging as a vital enabler in the next frontier of technological progress: physical AI. Where flashy data-center giants dominate headlines, BlackBerry’s QNX embedded software provides the trusted, real-time foundation that powers safe and predictable operation in the real world.…

Researchers at Boston Children’s Hospital, working with OpenAI, have demonstrated that artificial intelligence can significantly accelerate the diagnosis of rare genetic diseases that had previously eluded conventional medical analysis. Using OpenAI’s o3 Deep Research model to analyze the genomes and clinical records of 376 patients with undiagnosed conditions, researchers identified new diagnoses for 18 children, including cases involving neurodevelopmental disorders, neuromuscular diseases, early childhood psychosis, and previously unexplained child deaths. While researchers emphasized that AI is not a substitute for physicians or a tool for self-diagnosis, the findings suggest that artificial intelligence is becoming a powerful assistant capable of uncovering…

A recent study highlights the limitations of large-language model-based trading strategies, revealing that while these AI systems may show promise in short bursts, they ultimately fall short of outperforming a simple buy-and-hold approach over extended periods and across varying market conditions. The research demonstrates that AI bots, lacking true human-like adaptability, often play it too safe during strong bull markets and then overtrade aggressively during downturns, leading to missed opportunities and amplified losses—echoing the very emotional pitfalls they were designed to avoid in the free-market arena where individual judgment and disciplined investing have long driven prosperity. Sources Key Takeaways In-Depth…

There is a quiet revolution underway in medicine, and it isn’t happening in a hospital ward or a government lab—it’s unfolding inside powerful computer systems driven by artificial intelligence. For decades, researchers have chased cures for terminal diseases like ALS, pancreatic cancer, and advanced neurodegenerative disorders with limited success, often constrained by time, cost, and the sheer complexity of human biology. Now, AI presents a serious—and potentially transformative—opportunity to break through barriers that have long stalled progress. The question isn’t whether AI can contribute. It’s how far it can go, and whether we are willing to let it. At its…

Alphabet suffered one of its worst trading days of 2026 after investors erased roughly $270 billion in market value amid growing concerns that Google is losing its edge in the artificial intelligence race. The immediate catalyst was the departure of two of the company’s most prominent AI researchers—John Jumper to Anthropic and Noam Shazeer to OpenAI—raising fresh doubts about Google’s ability to retain elite talent despite massive investments in AI infrastructure. While Google remains one of the world’s dominant technology companies, Wall Street increasingly appears to believe that the AI race will be won not simply through spending but by…